Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00024622 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PET Scanning in Parkinson s Disease

StatusCompleted
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 456 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fields
  2. Publications: 3 to 4
  3. Re-verified, no change to tracked fields
  4. Re-verified, no change to tracked fields
  5. New version filed on ClinicalTrials.gov
Show 45 earlier versionsHide 45 earlier versions
  1. 11 versions Re-verified since Nov 19, 2025, no change to tracked fieldsv441-v451
  2. Enrollment target: 494 to 502v440
  3. 24 versions Re-verified since Dec 21, 2024, no change to tracked fieldsv416-v439
  4. Trial status: Recruiting to Completed Enrollment target: estimated 580 to confirmed 494v415 Show all 2 changesShow less
    • Enrollment target: estimated 580 to confirmed 494
  5. 8 versions Re-verified since Oct 25, 2024, no change to tracked fieldsv407-v414
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an in vivo positron emission tomography (PET) study of regional cerebral dopamine and blood flow in normal volunteers, persons with Parkinson s disease (both familial and sporadic), and those with schizophrenia spectrum disorders. The latter also sign consent for NIH approved protocol 89-M-0160, "Inpatient Evaluation of Neuropsychiatric Patients," PI: Daniel Eisenberg, M.D. Using PET with 6-\[F-18\] Fluoro-L-dopa (FDOPA) and (15)0-H2O in a single scan session, both presynaptic dopaminergic function and regional cerebral blood flow (rCBF) are assessed. The kinetic rate constant (Ki) for presynaptic dopaminergic uptake in striatum and other regions is calculated. We compare Ki across subject groups and relate the findings to rCBF. Findings are also related to allelic variation in genes of interest, for determination of which participants sign separate consent for NIH approved protocol 95-M-0150 Neurobiological Investigation of Patients with Schizophrenia Spectrum Disorders and Their Siblings, PI: Karen F. Berman, MD. We also draw comparisons between subjects with inherited vs. sporadic Parkinson s disease to determine whether the PET phenotype is the same in both groups, and we compare system-level, circuit-based pathophysiology across PD and schizophrenia groups. Each subject is further screened with an MRI to rule out structural abnormalities and also to further delineate areas of interest in the PET scans....
Trial Details
NCT Number NCT00024622
Lead Sponsor National Institute of Mental Health (NIMH)
Conditions Schizophrenia, Parkinson's Disease
Enrollment 502 participants
Start Date
Updated on ClinicalTrials.gov